Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival - 22/11/19
, J.-R. Barrière b , C. Clarot c , J.-P. Vabre d , B. Gentil Le Pecq e , Y. Duval f , P. Thomas g , D. Herman h , M. Grivaux i , D. Debieuvre j Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
Patients with metastatic non-small-cell lung cancer (NSCLC) who survive more than 2 years are considered long-term survivors (LTSs). The present study examined factors associated with long-term survival and collected information for future comparison.
Methods |
Clinical, molecular, and therapeutic data were collected from patients followed for primary stage IV (7th TNM classification) NSCLC within 2 years from diagnosis in the respiratory medicine departments of 53 French non-teaching hospitals. LTS and non-LTS records were compared. Factors associated with long-term survival were examined by univariate and multivariate analyses using logistic regression models.
Results |
Vital status at least 2 years after diagnosis was known for 1977 stage IV NSCLC patients; 220 (11.1%) were LTSs. On multivariate analysis, independent positive factors comprised: TTF-1(+) immunochemistry, EGFR-mutation, surgery, rescue radiotherapy, and targeted therapy. Independent negative factors comprised: prediagnosis weight loss>5kg, ECOG performance status>1, and primary radiotherapy.
Conclusions |
Molecular biology and targeted therapy were decisive for long-term survival. With their development and their widespread implementation in clinical practice, the percentage of LTSs is expected to grow. Factors determining long-term survival found in this study should be taken into account when considering treatment options for patients with stage IV NSCLC.
Le texte complet de cet article est disponible en PDF.Keywords : Carcinoma, Non-small-cell lung, Cancer survivors, General hospitals, Observational study, Prognosis factors
Plan
Vol 76
P. 38-44 - novembre 2019 Retour au numéro
Article précédent
- Chronic thromboembolic pulmonary hypertension suspicion after pulmonary embolism in cancer patients
- J. Catella-Chatron, A. Merah, E. De Magalhaes, N. Moulin, S. Accassat, C. Duvillard, P. Mismetti, L. Bertoletti
- Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension
- A. Seferian, X. Jaïs, L. Savale, M. Jevnikar, M.-R. Ghigna, J. Weatherald, S. Assoun, E. Fadel, G. Simonneau, O. Sitbon, M. Humbert, D. Montani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?